GSA Capital Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

GSA Capital Partners’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$424K	Buy	+789	New	+$404K	0.03%	1108
2025 Q4	–	Sell	-1,739	Closed	-$798K	–	1922
2025 Q3	$798K	Buy	+1,739	New	+$649K	0.07%	550
2023 Q2	–	Sell	-3,240	Closed	-$785K	–	1771
2023 Q1	$785K	Buy	+3,240	New	+$883K	0.08%	451
2022 Q1	–	Sell	-4,780	Closed	-$405K	–	1652
2021 Q4	$405K	Sell	4,780 -4,376	-48%	-$360K	0.05%	737
2021 Q3	$731K	Buy	9,156 +4,153	+83%	+$359K	0.07%	468
2021 Q2	$487K	Buy	+5,003	New	+$592K	0.05%	645
2021 Q1	–	Sell	-3,334	Closed	-$371K	–	1324
2020 Q4	$371K	Buy	+3,334	New	+$408K	0.06%	628
2020 Q1	–	Sell	-12,241	Closed	-$1.11M	–	1350
2019 Q4	$1.11M	Buy	12,241 +8,564	+233%	+$831K	0.13%	161
2019 Q3	$317K	Buy	+3,677	New	+$345K	0.04%	854
2018 Q3	–	Sell	-1,702	Closed	-$476K	–	1783
2018 Q2	$476K	Buy	+1,702	New	+$299K	0.02%	1183
2015 Q2	–	Sell	-894	Closed	-$61K	–	2090
2015 Q1	$61K	Buy	+894	New	+$76.7K	﹤0.01%	2047

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

GSA Capital Partners's MDGL Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 789 shares worth $424K. The stake represents 0.03% of the portfolio and ranks #1108 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in MDGL as recently as Q3 2025.

GSA Capital Partners first reported a position in MDGL in Q1 2015 and has held it in 11 quarters since. The position peaked at $1.11M in Q4 2019. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

GSA Capital Partners held 789 shares of Madrigal Pharmaceuticals worth $424K as of Q2 2026.
Madrigal Pharmaceuticals was a new GSA Capital Partners position in Q2 2026.
Madrigal Pharmaceuticals made up 0.03% of GSA Capital Partners's portfolio in Q2 2026, its #1108 holding.
GSA Capital Partners first reported a position in Madrigal Pharmaceuticals in Q1 2015 and has held it in 11 quarters since.
GSA Capital Partners's Madrigal Pharmaceuticals position peaked at $1.11M in Q4 2019.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.